The Impact Of Complete Chemotherapy Stop On The Overall Survival Of Patients With Advanced Colorectal Cancer In First-line Setting: A Meta-analysis Of Randomized Trials

dc.creatorLima Pereira
dc.creatorAllan Andresson; De Mendonca Rego
dc.creatorJuliana Florinda; Munhoz
dc.creatorRodrigo Ramela; Hoff
dc.creatorPaulo Marcelo; Sasse
dc.creatorAndre Deeke; Riechelmann
dc.creatorRachel P.
dc.date2015-Nov
dc.date2016-06-07T13:21:39Z
dc.date2016-06-07T13:21:39Z
dc.date.accessioned2018-03-29T01:41:25Z
dc.date.available2018-03-29T01:41:25Z
dc.identifier
dc.identifierThe Impact Of Complete Chemotherapy Stop On The Overall Survival Of Patients With Advanced Colorectal Cancer In First-line Setting: A Meta-analysis Of Randomized Trials. Taylor & Francis Ltd, v. 54, p. 1737-1746 Nov-2015.
dc.identifier0284-186X
dc.identifierWOS:000366669900006
dc.identifier10.3109/0284186X.2015.1044022
dc.identifierhttp://www.tandfonline.com/doi/full/10.3109/0284186X.2015.1044022
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/243106
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1306804
dc.descriptionBackground. The impact of the duration of chemotherapy on the overall survival of patients with metastatic colorectal cancer (mCRC) is controversial and studies have failed to define a clear standard.Methods. We searched medical literature databases and oncology conferences proceedings for randomized controlled trials (RCT) that compared the overall survival of mCRC patients who received continuous first-line chemotherapy until disease progression versus those who were offered complete treatment stop after a fixed number of cycles. Studies including targeted agents were also included. A meta-analysis of reported hazard ratios (HRs) for survival was performed.Results. We retrieved 240 trials, of which six were eligible and five were included in the pooled analysis of overall survival (N = 3061). The overall survival between continuously delivered chemotherapy and complete stop was not statistically different (HR = 0.93, 95% CI 0.85-1.02; p = 0.12; I-2 = 5%). The results are similar when we analyzed separately the trials performing randomization before versus after induction therapy. The median chemotherapy free interval in the complete stop group was 3.9 months (3.6-4.3 months). Chemotherapy administered until progression was associated with more adverse effects and impaired quality of life.Conclusion. Compared with first-line continuous chemotherapy administered until disease progression, complete treatment stop did not have a detrimental impact on the overall survival of patients with mCRC. Identification of predictive biomarkers could help clinicians to select the patients who would benefit from continuous cancer-directed therapies.
dc.description54
dc.description10
dc.description
dc.description1737
dc.description1746
dc.description
dc.description
dc.description
dc.languageen
dc.publisherTAYLOR & FRANCIS LTD
dc.publisher
dc.publisherABINGDON
dc.relationACTA ONCOLOGICA
dc.rightsembargo
dc.sourceWOS
dc.subjectCell Lung-cancer
dc.subjectFluorouracil Plus Leucovorin
dc.subjectPhase-iii
dc.subjectCombination Chemotherapy
dc.subjectClinical-trials
dc.subjectBreast-cancer
dc.subjectOxaliplatin
dc.subjectIntermittent
dc.subjectIrinotecan
dc.subjectTherapy
dc.titleThe Impact Of Complete Chemotherapy Stop On The Overall Survival Of Patients With Advanced Colorectal Cancer In First-line Setting: A Meta-analysis Of Randomized Trials
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución